Stocks to Keep Your Eyes on: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) , Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR)

On 4/18/2017, Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed at $49.73 in last trading day. After noting the initial trading entry at $50.76, it reached to a day’s high of $50.86 and moved to a day’s low of $49.14. The recent daily volume was 762.48 thousand as contrast to it’s an average volume of 952.05 thousand.

Technical Indicators:

The last close of the Alnylam Pharmaceuticals, Inc. stock reflects that it traded -3.34% from its 50-day moving average of $51.45. The stock traded above +11.87% to its 200-day MA of $44.45. Furthermore, it moved  lower -37.92% from its 52-week high of $80.11 and +58.48% up from $31.38, which is 52-week low of the stock.

Alnylam Pharmaceuticals, Inc.’s (ALNY) moved with shift of 0.97% in the past week. Over the last three months, the shares of the company have changed 30.12% and performed 40.80% over the last six months. The stock currently has Monthly Volatility of 4.55% and Weekly Volatility of 3.58%.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) finalized the last transaction at value of $1.08, with a daily change of -1.82% or -0.02 points. The company maintained volume of 707.74 thousand shares. In past trading day, the stock hit the maximum price of $1.12 and touched to minimum value of $0.99. It has a market cap of $ 12.55M.

Technical Indicators:

As of last trade close, the stock is trading  downside -71.20% from its one year high of $3.75 and moved +13.68% upward from $0.95, which is one year low of the stock.

The stock traded below -45.08% from its 50-day moving average of $1.97. Furthermore, the stock moved -56.75% to its 200-day MA of $ 2.50.

During the last month, Ritter Pharmaceuticals’s (RTTR) has changed -52.21% and performed -36.47% over the last 6 months. The mean rating score for this stock is at 2.20. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 16.38% in recent month and observed Weekly Volatility of 21.58%.

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. The company’s RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. Its RP-G28 has been studied in a Phase 2b/3 clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.


Leave a Reply

Your email address will not be published. Required fields are marked *